Información del producto
PF-06649283 is a drug that binds to the BACE1 enzyme and inhibits its activity. It is currently being investigated as a potential treatment for Alzheimer's disease, although it has not yet been approved by the FDA. PF-06649283 binds to the c-terminal domain of BACE1 and prevents it from degrading amyloid precursor protein (APP). This results in an increase in amyloid beta peptides, which are thought to be involved in the pathogenesis of Alzheimer's disease. The drug also inhibits other proteases such as cathepsin D, which may contribute to its therapeutic effects. In addition, PF-06649283 has been shown to activate microglia cells in primary hippocampal cultures. These cells have been implicated in neurodegenerative diseases such as Parkinson's and Alzheimer's disease and have been shown to produce inflammatory cytokines that can destroy neurons.
PF-06649283 also blocks cell surface receptors on cerebellar granule
Propiedades químicas
Consulta técnica sobre: 3D-WPC58517 PF-06649283
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
